Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Elevated Serum Tumor Markers (HE4 and ROMA Score) and Increased Treg Cells Distinguished Ovarian Cancer and Benign Tumor

The Indonesian Biomedical Journal · Vol. 16 No. 3 (2024) · hlm. 248–254

DOI
10.18585/inabj.v16i3.3027
ISSN
2085-3297, 2355-9179
Terbit
2024-06-26
Penerbit
Secretariat of The Indonesian Biomedical Journal
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc/4.0/

Abstrak

BACKGROUND: Tumor markers such as human epididymis protein 4 (HE4), cancer antigen 125 (CA-125), and risk of ovarian malignancy algorithm (ROMA) are frequently utilized for diagnostic and prognostic purposes. Lymphocytes, essential immune cells, play a significant role in eliminating cancer cells. However, the precise correlation between tumor markers and lymphocytes remains incompletely elucidated. The aim of this study was to explore the correlation between tumor markers and lymphocyte subtype profiles in differentiating ovarian cancer and benign tumors.METHODS: This was a cross-sectional study involving 12 ovarian cancer and 17 benign ovarian tumor patients. Blood samples were collected for the characterization of T lymphocytes, B lymphocytes, natural killer (NK), and T regulatory (Treg), which were analyzed using flowcytometry. Additionally, tumor markers HE4 and CA-125 were measured from patient serum using the chemiluminescent microparticle immunoassay (CMIA) method.RESULTS: Benign ovarian tumors and ovarian cancer can be distinguished by a significant increase in HE4 levels (p=0.004), ROMA (p=0.004), and Treg cells (CD4+/CD25+/FOXP3+, p=0.017). Furthermore, the correlation between tumor markers and lymphocytes indicates that an increase in ROMA was weakly correlated with an increase in the percentage of T regulatory cells (CD4+/CD25+/FOXP3+, r=0.553, p=0.006) and B lymphocytes (CD19+, r=0.528, p=0.010), accompanied by a decrease in the number of T lymphocytes (CD3+, r=-0.598, p=0.003), T helper lymphocytes (CD3+CD4+, r=-0.594, p=0.003), and cytotoxic lymphocytes (CD3+CD8+, r=-0.510, p=0.013).CONCLUSION: The elevation of serum tumor markers (HE4 and ROMA) accompanied by an increase in Treg cells can distinguish between benign ovarian tumor patients and ovarian cancer patients.KEYWORDS: tumor marker, CA-125, HE4, ROMA, subtype of lymphocytes, ovarian cancer

Kata kunci

Jaringan kolaborasi para penulis

35 penulis · 150 tautan kepenulisan bersama · 89 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Dr. Hasan Sadikin General Hospital
  • University of Indonesia
  • National Nuclear Energy Agency of Indonesia
  • Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo
  • Padjadjaran University
  • Muhammadiyah University of Yogyakarta
  • Universitas Sumatera Utara
  • Organisasi lain
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Budiningsih SiregarRumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo3
Irwan RamliRumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo3
Tjahya KurjanaDr. Hasan Sadikin General Hospital3
Teja KisnantoNational Nuclear Energy Agency of Indonesia3
Devita TetrianaNational Nuclear Energy Agency of Indonesia3
Setiawan SoetopoDr. Hasan Sadikin General Hospital3
Maringan Diapari Lumban TobingDr. Hasan Sadikin General Hospital2
Miftakh Nur RahmanPadjadjaran University2
Indriyanti Rafi SukmawatiHasanuddin University2
Bethy Suryawathy HernowoDr. Hasan Sadikin General Hospital1
Zubaidah AlatasNational Nuclear Energy Agency of Indonesia1
A. AndrionoRumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo1
Yanti LusiyantiNational Nuclear Energy Agency of Indonesia1
Mohamad SadikinUniversity of Indonesia1
Bethy Surjawathy HernowoDr. Hasan Sadikin General Hospital1
Andri AndrijonoRumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo1
Maringan Dl TobingDr. Hasan Sadikin General Hospital1
Sadam Fajar ShodiqMuhammadiyah University of Yogyakarta1
AndrionoRumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo1
Bethy SuryawathiDr. Hasan Sadikin General Hospital1
Jose R. L. BatubaraUniversity of Indonesia1
Siska Mayasari LubisUniversitas Sumatera Utara1
Harun Alrasyid DamanikUniversitas Sumatera Utara1
Melisa Intan BarlianaPadjadjaran University1
Ajeng DiantiniPadjadjaran University1
Ani Retno PrijantiUniversity of Indonesia1
Heri WibowoUniversity of Indonesia1
Dicky L. TahaparyUniversity of Indonesia1
Irma Melyani PuspitasariPadjadjaran University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S2764892910, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Elevated Serum Tumor Markers (HE4 and ROMA Score) and Increased Treg Cells Distinguished Ovarian Cancer and Benign Tumor</dc:title><dc:creator>Manuel Hutapea</dc:creator><dc:creator>Syamsudin Syamsudin</dc:creator><dc:creator>Iin Kurnia</dc:creator><dc:creator>Miswar Fattah</dc:creator><dc:creator>Ujang Saeful Hikmat</dc:creator><dc:creator>Vinessa Gracia Putri</dc:creator><dc:subject>ovarian cancer</dc:subject><dc:subject>benign ovarian tumors</dc:subject><dc:subject>HE4</dc:subject><dc:subject>CA125</dc:subject><dc:subject>regulatory T cells</dc:subject><dc:subject>tumor markers</dc:subject><dc:subject>lymphocyte subsets</dc:subject><dc:subject>differential diagnosis</dc:subject><dc:subject>Foxp3</dc:subject><dc:subject>CD4+CD25+ Treg</dc:subject><dc:description xml:lang="en">BACKGROUND: Tumor markers such as human epididymis protein 4 (HE4), cancer antigen 125 (CA-125), and risk of ovarian malignancy algorithm (ROMA) are frequently utilized for diagnostic and prognostic purposes. Lymphocytes, essential immune cells, play a significant role in eliminating cancer cells. However, the precise correlation between tumor markers and lymphocytes remains incompletely elucidated. The aim of this study was to explore the correlation between tumor markers and lymphocyte subtype profiles in differentiating ovarian cancer and benign tumors.METHODS: This was a cross-sectional study involving 12 ovarian cancer and 17 benign ovarian tumor patients. Blood samples were collected for the characterization of T lymphocytes, B lymphocytes, natural killer (NK), and T regulatory (Treg), which were analyzed using flowcytometry. Additionally, tumor markers HE4 and CA-125 were measured from patient serum using the chemiluminescent microparticle immunoassay (CMIA) method.RESULTS: Benign ovarian tumors and ovarian cancer can be distinguished by a significant increase in HE4 levels (p=0.004), ROMA (p=0.004), and Treg cells (CD4+/CD25+/FOXP3+, p=0.017). Furthermore, the correlation between tumor markers and lymphocytes indicates that an increase in ROMA was weakly correlated with an increase in the percentage of T regulatory cells (CD4+/CD25+/FOXP3+, r=0.553, p=0.006) and B lymphocytes (CD19+, r=0.528, p=0.010), accompanied by a decrease in the number of T lymphocytes (CD3+, r=-0.598, p=0.003), T helper lymphocytes (CD3+CD4+, r=-0.594, p=0.003), and cytotoxic lymphocytes (CD3+CD8+, r=-0.510, p=0.013).CONCLUSION: The elevation of serum tumor markers (HE4 and ROMA) accompanied by an increase in Treg cells can distinguish between benign ovarian tumor patients and ovarian cancer patients.KEYWORDS: tumor marker, CA-125, HE4, ROMA, subtype of lymphocytes, ovarian cancer</dc:description><dc:publisher>Secretariat of The Indonesian Biomedical Journal</dc:publisher><dc:date>2024-06-26</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>http://dx.doi.org/10.18585/inabj.v16i3.3027</dc:identifier><dc:identifier>10.18585/inabj.v16i3.3027</dc:identifier><dc:source>The Indonesian Biomedical Journal; Vol 16 No 3 (2024); 248-254</dc:source><dc:source>2085-3297</dc:source><dc:source>2355-9179</dc:source><dc:language>en</dc:language><dc:relation>https://inabj.org/index.php/ibj/article/download/3027/713</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>